Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRBP Corbus Pharmaceuticals

Closed 08-13 16:00:00 EDT

10.08

+0.32

+3.28%

盘后10.32

+0.24+2.38%

19:34 EDT

High10.39	Low9.68	Vol696.20K
Open10.05	D1 Closing9.76	Amplitude7.27%
Mkt Cap194.96M	Tradable Cap175.56M	Total Shares19.34M
T/O6.98M	T/O Rate4.00%	Tradable Shares17.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRBP","market":"US","secType":"STK","nameCN":"Corbus Pharmaceuticals","latestPrice":10.08,"timestamp":1786651200000,"preClose":9.76,"halted":0,"volume":696201,"hourTrading":{"tag":"盘后","latestPrice":10.32,"preClose":10.08,"latestTime":"19:34 EDT","volume":1159,"amount":11700.9057,"timestamp":1786664047116,"change":0.24,"changeRate":0.02381,"amplitude":0.031032},"delay":0,"changeRate":0.03278688524590167,"floatShares":17416483,"shares":19341300,"eps":-6.088859,"marketStatus":"Closed","change":0.32,"latestTime":"08-13 16:00:00 EDT","open":10.05,"high":10.39,"low":9.68,"amount":6978048.382437,"amplitude":0.072746,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.088859,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786694400000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.76,"preHourTrading":{"tag":"盘前","latestPrice":10.16,"preClose":9.76,"latestTime":"09:29 EDT","volume":1838,"amount":18373.07993,"timestamp":1786627799999,"change":0.4,"changeRate":0.040984,"amplitude":0.053279},"postHourTrading":{"tag":"盘后","latestPrice":10.32,"preClose":10.08,"latestTime":"19:34 EDT","volume":1159,"amount":11700.9057,"timestamp":1786664047116,"change":0.24,"changeRate":0.02381,"amplitude":0.031032},"volumeRatio":1.901839,"impliedVol":1.1853,"impliedVolPercentile":0.6614},"requestUrl":"/m/hq/s/CRBP","defaultTab":"news","newsList":[{"id":"2659130694","title":"Mizuho Adjusts PT on Corbus Pharmaceuticals to $33 From $34, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2659130694","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659130694?lang=en_us&edition=fundamental","pubTime":"2026-08-13 17:22","pubTimestamp":1786612960,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings (CRBP) has an average rating of buy and mean price target of $34.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic researc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRBP","MFG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659183427","title":"Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Wednesday When Compared to Competitors Despite Daily Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2659183427","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659183427?lang=en_us&edition=fundamental","pubTime":"2026-08-13 05:21","pubTimestamp":1786569660,"startTime":"0","endTime":"0","summary":"DJ Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily GainsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  rose 2.63% to $9.76 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index  rising 0.54% to 26,588.49 and the Dow Jones Industrial Average  falling 0.04% to 53,770.27.This was the stock's second consecutive day of gains.Corbus Pharmaceuticals Holdings Inc. closed 52.53% below its 52-week high of $20.56, which the company achieved on October 20th.The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Vanda Pharmaceuticals Inc.  rose 5.27% to $5.19, Fortress Biotech Inc.  rose 5.36% to $2.75, and Viking Therapeutics Inc.  rose 0.65% to $34.02.Data source: Dow Jones Market Data, FactSet. Data compiled August 12, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659297183","title":"Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659297183","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659297183?lang=en_us&edition=fundamental","pubTime":"2026-08-13 05:10","pubTimestamp":1786569008,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aura Biosciences Inc (AURA) and Corbus Pharmaceutica...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-aura-biosciences-inc-aura-corbus-pharmaceuticals-crbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-aura-biosciences-inc-aura-corbus-pharmaceuticals-crbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRBP","BK4139","AURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659188855","title":"Corbus Chief Business Officer Nishant Saxena Acquires 2,600 Shares Worth $25,037.44","url":"https://stock-news.laohu8.com/highlight/detail?id=2659188855","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659188855?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:31","pubTimestamp":1786566678,"startTime":"0","endTime":"0","summary":"Corbus Chief Business Officer Nishant Saxena acquires 2,600 shares worth $25,037.44Corbus Pharmaceuticals Chief Business Officer Nishant C. Saxena bought 2,600 common shares at USD 9.63 each.Beneficia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLccjC59:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Corbus Chief Business Officer Nishant Saxena Acquires 2,600 Shares Worth $25,037.44","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658896974","title":"RBC Capital Sticks to Their Buy Rating for Corbus Pharmaceuticals (CRBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658896974","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658896974?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:06","pubTimestamp":1786532804,"startTime":"0","endTime":"0","summary":"In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals, with a price target of $36.00. Accor...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-buy-rating-for-corbus-pharmaceuticals-crbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-buy-rating-for-corbus-pharmaceuticals-crbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658607951","title":"Corbus Pharma CFO Sean Moran Sells 12,000 Shares for $120,971","url":"https://stock-news.laohu8.com/highlight/detail?id=2658607951","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658607951?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:33","pubTimestamp":1786393982,"startTime":"0","endTime":"0","summary":"Corbus Pharma CFO Sean Moran sells 12,000 shares for $120,971Corbus Pharmaceuticals CFO Sean F. Moran sold 12,000 common shares on Aug. 7, 2026 at a weighted average price of USD 10.08.Directly held s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL5pJJyp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corbus Pharma CFO Sean Moran Sells 12,000 Shares for $120,971","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936951","title":"Corbus Pharmaceuticals Holdings Inc. Stock Falls 7.0%, Underperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936951","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936951?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:32","pubTimestamp":1786393920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc. slid 7.0% to $9.46 on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index falling 0.3% to 26,605.36 and Dow Jones Industrial Average falling 0.1% to 53,975.98.The stock's fall snapped a four-day winning streak.Corbus Pharmaceuticals Holdings Inc. closed 54.0% short of its 52-week high of $20.56, which the company achieved on October 20th.The stock underperformed when compared to some of its peers, as Vanda Pharmaceuticals Inc. rose 0.4% to $5.02, Fortress Biotech Inc. rose 3.0% to $2.75, and Viking Therapeutics Inc. rose 0.53% to $34.44.Trading volume totaled 335,566, compared to the 50-day average of 412,692.Data source: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657662986","title":"Corbus Pharmaceuticals - to Offer and Sell Common Stock up to $127.50 Mln Through Jefferies - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2657662986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657662986?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:44","pubTimestamp":1786135454,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nFWN4440X4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657629869","title":"Corbus Pharmaceuticals - Enters Open Market Sale Agreement with Jefferies - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2657629869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657629869?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:44","pubTimestamp":1786135454,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nFWN4440X4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626783","title":"Corbus Pharmaceuticals Holdings Inc. Stock Rises 4.4%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626783","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626783?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:35","pubTimestamp":1786134900,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc. rallied 4.4% to $10.17 on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 1.3% to 26,690.62 and the Dow Jones Industrial Average rising 0.3% to 54,036.93.This was the stock's fourth consecutive day of gains.Corbus Pharmaceuticals Holdings Inc. closed 50.5% short of its 52-week high of $20.56, which the company reached on October 20th.The stock outperformed some of its peers, as Vanda Pharmaceuticals Inc. fell 2.2% to $5.00, Fortress Biotech Inc. fell 3.6% to $2.67, and Viking Therapeutics Inc. rose 2.88% to $34.26.Trading volume totaled 352,885, compared to the 50-day average of 447,114.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657649579","title":"Corbus Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2657649579","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657649579?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:19","pubTimestamp":1786108740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRBP/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657864519","title":"Corbus Pharmaceuticals Holdings : Oppenheimer Cuts Target Price to $48 from $52","url":"https://stock-news.laohu8.com/highlight/detail?id=2657864519","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657864519?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:34","pubTimestamp":1786106042,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nAZN4TCM2Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657301396","title":"Corbus Pharmaceuticals Holdings, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657301396","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657301396?lang=en_us&edition=fundamental","pubTime":"2026-08-06 22:23","pubTimestamp":1786026224,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings, Inc. reports results for the quarter ended June 30 - Earnings SummaryCorbus Pharmaceuticals Holdings, Inc.CRBP.OQreported a quarterly adjusted loss of $1.81 per share ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4432AQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657313906","title":"Corbus Pharmaceuticals Q2 EPS $(1.81) Misses $(1.26) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657313906","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657313906?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:32","pubTimestamp":1786019545,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(1.26) by 43.65 percent. This is a 25.69 percent decrease over losses of $(1.44) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60993190/corbus-pharmaceuticals-q2-eps-1-81-misses-1-26-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657636751","title":"Corbus Q2 FY26 Net Loss Widens to $35.04 Million; Loss Per Share Increases to $1.81","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636751","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657636751?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:04","pubTimestamp":1786017881,"startTime":"0","endTime":"0","summary":"Corbus Q2 FY26 net loss widens to $35.04 million; loss per share increases to $1.81Corbus posted a net loss of USD 35.04 million in Q2 2026, widening from USD 17.66 million a year earlier; loss per sh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL23M0Bs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657557998","title":"Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2657557998","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657557998?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:22","pubTimestamp":1785964920,"startTime":"0","endTime":"0","summary":"DJ Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  rallied 1.81% to $9.57 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average  rising 0.49% to 54,349.12 and the NASDAQ Composite Index  falling 0.83% to 26,363.44.This was the stock's second consecutive day of gains.Corbus Pharmaceuticals Holdings Inc. closed 53.45% short of its 52-week high of $20.56, which the company achieved on October 20th.The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Vanda Pharmaceuticals Inc.  fell 4.50% to $5.09, Fortress Biotech Inc.  rose 2.57% to $2.79, and Viking Therapeutics Inc.  rose 1.73% to $33.51.Trading volume  remained 291,144 below its 50-day average volume of 525,353.Data source: Dow Jones Ma","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657567251","title":"Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2657567251","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657567251?lang=en_us&edition=fundamental","pubTime":"2026-08-05 05:20","pubTimestamp":1785878400,"startTime":"0","endTime":"0","summary":"DJ Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  advanced 5.38% to $9.40 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index  rising 2.59% to 26,584.99 and the Dow Jones Industrial Average  rising 1.71% to 54,085.88.The stock's rise snapped a two-day losing streak.Corbus Pharmaceuticals Holdings Inc. closed 54.28% below its 52-week high of $20.56, which the company reached on October 20th.The stock outperformed some of its competitors Tuesday, as Vanda Pharmaceuticals Inc.  rose 1.91% to $5.33, Fortress Biotech Inc.  fell 1.45% to $2.72, and Viking Therapeutics Inc.  rose 1.01% to $32.94.Trading volume  remained 268,189 below its 50-day average volume of 533,096.Data source: Dow Jones Market Data, FactSet. Data compiled August 4, 2","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657564199","title":"Corbus Pharma CMO Nicacio Leonardo Viana Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2657564199","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657564199?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:31","pubTimestamp":1785875511,"startTime":"0","endTime":"0","summary":"Corbus Pharma CMO Nicacio Leonardo Viana files initial beneficial ownership statementCorbus Pharmaceuticals filed a Form 3 for Chief Medical Officer Nicacio Leonardo Viana.Disclaimer:This news brief w","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL9BVnFB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656967554","title":"Corbus reports last patient completes last visit in CANYON-1 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2656967554","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656967554?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:55","pubTimestamp":1785851749,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals (CRBP) announced the last patient has completed their last clinical visit in the company’s CANYON-1 Phase 1b clinical trial ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corbus-reports-last-patient-completes-last-visit-in-canyon-1-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corbus-reports-last-patient-completes-last-visit-in-canyon-1-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRBP","GDOC","HYLG","MEDX","NVIB","BK4139","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656556644","title":"Corbus Says Phase 1b Canyon-1 Obesity Trial of CRB-913 Reaches Last Patient Last Visit","url":"https://stock-news.laohu8.com/highlight/detail?id=2656556644","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656556644?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:33","pubTimestamp":1785846827,"startTime":"0","endTime":"0","summary":"Corbus says Phase 1b CANYON-1 obesity trial of CRB-913 reaches last patient last visitCorbus reached last patient last visit in its Phase 1b CANYON-1 trial of obesity drug CRB-913.Topline results were","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL2h92l7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","LU2095319765.USD","IE00BGHQF748.EUR","NDAQ","IE00BN0W2W23.USD","IE00BKPKM429.USD","LU0314104364.USD","IE00BN0W2V16.EUR","SG9999014021.USD","SG9999014039.USD","SG9999014013.SGD","BK4585","BCDF","SG9999014005.SGD","BK4588","LU2210150020.SGD","BK4112","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BN0W2T93.GBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corbuspharma.com","stockEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":0.0796},{"period":"3month","weight":-0.1853},{"period":"6month","weight":0.291},{"period":"1year","weight":0.0893},{"period":"ytd","weight":0.199}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":0.0311},{"period":"3month","weight":0.0325},{"period":"6month","weight":0.1331},{"period":"1year","weight":0.202},{"period":"ytd","weight":0.1328}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.363358},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.048678},{"month":3,"riseRate":0.636364,"avgChangeRate":0.197993},{"month":4,"riseRate":0.545455,"avgChangeRate":0.046477},{"month":5,"riseRate":0.583333,"avgChangeRate":0.055971},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.044414},{"month":7,"riseRate":0.25,"avgChangeRate":-0.049826},{"month":8,"riseRate":0.666667,"avgChangeRate":0.095039},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.086452},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.124298},{"month":11,"riseRate":0.727273,"avgChangeRate":0.130055},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.132264}],"exchange":"NASDAQ","name":"Corbus Pharmaceuticals","nameEN":"Corbus Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Corbus Pharmaceuticals(CRBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Corbus Pharmaceuticals,CRBP,Corbus Pharmaceuticals股票,Corbus Pharmaceuticals股票老虎,Corbus Pharmaceuticals股票老虎国际,Corbus Pharmaceuticals行情,Corbus Pharmaceuticals股票行情,Corbus Pharmaceuticals股价,Corbus Pharmaceuticals股市,Corbus Pharmaceuticals股票价格,Corbus Pharmaceuticals股票交易,Corbus Pharmaceuticals股票购买,Corbus Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Corbus Pharmaceuticals(CRBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction